- Home
- BIAF vs NDRA Comparison
BIAF vs NDRA Comparison
Compare BIAF & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | NDRA |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 7.3M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BIAF | NDRA |
|---|---|---|
| Price | $1.18 | $5.05 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | 70.6K | ★ 83.8K |
| Earning Date | 11-14-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,776,739.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $2.90 |
| 52 Week High | $46.53 | $11.96 |
Technical Indicators
Market Signals| Indicator | BIAF | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | 31.88 | 44.09 |
| Support Level | $1.18 | $4.80 |
| Resistance Level | $1.37 | $5.18 |
| Average True Range (ATR) | 0.11 | 0.37 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 6.56 | 19.62 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.